Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Revolution Medicines (RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:30 a.m. ET.
The presentation will be accessible via live webcast through the company's investor relations website under the 'Events & Presentations' section. Interested parties can view a replay of the webcast on the same platform for at least 14 days following the conference.
Revolution Medicines (RVMD), un'azienda oncológica in fase clinica concentrata sullo sviluppo di terapie mirate per i cancro dipendente da RAS, ha annunciato la sua partecipazione alla prossima Guggenheim Securities SMID Cap Biotech Conference. Il CEO e presidente dell'azienda, Mark A. Goldsmith, M.D., Ph.D., parteciperà a una chiacchierata informale programmata per mercoledì 5 febbraio 2025, alle 10:30 a.m. ET.
La presentazione sarà accessibile tramite una diretta web nel sito web delle relazioni con gli investitori dell'azienda, sotto la sezione 'Eventi e Presentazioni'. Le parti interessate potranno visualizzare una registrazione della diretta nella stessa piattaforma per almeno 14 giorni dopo la conferenza.
Revolution Medicines (RVMD), una empresa oncológica en etapa clínica enfocada en el desarrollo de terapias dirigidas para cánceres adictos a RAS, ha anunciado su participación en la próxima Guggenheim Securities SMID Cap Biotech Conference. El CEO y presidente de la compañía, Mark A. Goldsmith, M.D., Ph.D., participará en una charla informal programada para miércoles 5 de febrero de 2025, a las 10:30 a.m. ET.
La presentación será accesible a través de una transmisión web en vivo a través del sitio web de relaciones con inversionistas de la compañía, en la sección 'Eventos y Presentaciones'. Las partes interesadas podrán ver una repetición de la transmisión en la misma plataforma durante al menos 14 días después de la conferencia.
Revolution Medicines (RVMD), RAS 의존성 암을 위한 표적 치료제를 개발하는 임상 단계의 종양학 회사가 구겐하임 증권 SMID 캡 생명공학 회의에 참여한다고 발표했습니다. 회사의 CEO이자 회장인 Mark A. Goldsmith, M.D., Ph.D.가 2025년 2월 5일 수요일 오전 10:30 ET에 예정된 화로 토크에 참여합니다.
발표는 회사 투자자 관계 웹사이트의 '이벤트 및 발표' 섹션을 통해 라이브 웹캐스트로 시청할 수 있습니다. 관심 있는 당사자는 회의 후 최소 14일 동안 같은 플랫폼에서 웹캐스트의 재방송을 볼 수 있습니다.
Revolution Medicines (RVMD), une entreprise d'oncologie en phase clinique axée sur le développement de thérapies ciblées pour les cancers dépendants de RAS, a annoncé sa participation à la prochaine Guggenheim Securities SMID Cap Biotech Conference. Le PDG et président de l'entreprise, Mark A. Goldsmith, M.D., Ph.D., participera à une discussion informelle prévue pour le mercredi 5 février 2025 à 10h30 ET.
La présentation sera accessible par le biais d'un webcast en direct sur le site des relations investisseurs de l'entreprise, dans la section 'Événements & Présentations'. Les parties intéressées pourront visionner une rediffusion du webcast sur la même plateforme pendant au moins 14 jours après la conférence.
Revolution Medicines (RVMD), ein klinisches Onkologieunternehmen, das sich auf die Entwicklung zielgerichteter Therapien für RAS-abhängige Krebserkrankungen konzentriert, hat seine Teilnahme an der bevorstehenden Guggenheim Securities SMID Cap Biotech Conference bekannt gegeben. Der CEO und Vorsitzende des Unternehmens, Mark A. Goldsmith, M.D., Ph.D., wird an einem geplanten Fireside-Chat am Mittwoch, den 5. Februar 2025, um 10:30 Uhr ET teilnehmen.
Die Präsentation wird über einen Live-Webcast über die Investor-Relations-Website des Unternehmens im Abschnitt 'Veranstaltungen & Präsentationen' zugänglich sein. Interessierte Parteien können die Wiederholung des Webcasts auf derselben Plattform für mindestens 14 Tage nach der Konferenz ansehen.
- None.
- None.
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET.
To access the live webcast of the presentation, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
When is Revolution Medicines (RVMD) presenting at the Guggenheim Securities SMID Cap Biotech Conference?
How can investors access RVMD's presentation at the Guggenheim Securities conference?
How long will the replay of RVMD's Guggenheim Securities conference presentation be available?
What type of cancers does Revolution Medicines (RVMD) focus on treating?
